Molecular action of methotrexate in inflammatory diseases - Test2 - elhamkhani - TriplyDB

Molecular action of methotrexate in inflammatory diseases

Molecular action of methotrexate in inflammatory diseases

http://www.wikidata.org/entity/Q24534771

about

Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients The continuing challenges of leprosy Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols Wegener's granulomatosis: current and upcoming therapies Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control New Oral Therapies for Psoriasis: A Comprehensive Review The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis.Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: An observational study.Methotrexate carried in lipid core nanoparticles reduces myocardial infarction size and improves cardiac function in rats.Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms.Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal.Adenosine signaling during acute and chronic disease states Adenosine and bone metabolism.Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritis.Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammation Pharmacogenetics in the rheumatic diseases A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis.Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?Adenosine in fibrosis.PharmGKB summary: methotrexate pathway.B-vitamin deficiency is protective against DSS-induced colitis in mice.Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK.Evaluation of the concomitant use of methotrexate and curcumin on Freund's complete adjuvant-induced arthritis and hematological indices in rats.Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis Possible targeting of G protein coupled receptors to manipulate inflammation in vivo using synthetic and natural ligands.Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities.Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression.Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis.Release of Periplasmic Nucleotidase Induced by Human Antimicrobial Peptide in E. coli Causes Accumulation of the Immunomodulator Adenosine Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?Pharmacogenetic approaches to rheumatoid arthritis.Pharmacogenetics of methotrexate.Rutin attenuates intestinal toxicity induced by Methotrexate linked with anti-oxidative and anti-inflammatory effects Two inhibitors of DNA-synthesis lead to inhibition of cytokine production via a different mechanism.Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy.Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy.Review article: practical management of inflammatory bowel disease patients taking immunomodulators.Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease.

P2860

Q21131938-485360CD-D041-4D02-B479-EB02981842F8 Q24545809-DE40276E-6C8F-4D9E-8BD2-1A5CBA0BE192 Q24793159-98C3EB2D-BB70-4A75-9396-90630FABA9DB Q24804964-78439B2B-000D-4BB8-8CF1-E69D8A021CB2 Q24817102-45D9D90F-4CDF-431D-AD2F-AA07665169BE Q28071475-2E101B10-A47B-4E4C-9D5D-6B478F97FB83 Q31132502-5C7194BD-50CE-4DF5-A441-37BEB10CFA7A Q33435868-72556252-DFC6-4163-A2DD-2428D024DC9C Q33713970-927D9ECC-8816-4130-A83B-B072B81B7C6A Q33747444-1F166047-B84F-4AF2-BD34-EB1C008227DA Q33940441-369A3E8F-AD83-4EF8-802D-F639DE7C409F Q34035228-9594F653-0199-4C08-8B86-090C06E91F85 Q34036039-8C2A9CB8-3F9F-4789-AA13-9C2492F0FE4B Q34153004-3572AE02-599C-42B5-A50A-3D3371492D96 Q34292553-7C2EEED4-0399-4125-AE18-251DE1AAB6F8 Q34293811-91E09D91-94D5-451D-B385-EA42BBDD130C Q34358310-D8B568D4-FAA0-4CA1-A1D1-7ED14039826C Q34413330-9EF914A5-3292-4018-BA2E-A8DCD0CBFB72 Q34559803-478CF2D4-19F9-4C73-ABE0-189A576C034F Q35085245-810AF2F1-3820-45B7-9DEF-22FE4D606AFE Q35115680-DEA95A5B-93FE-4E27-9C5C-A8267407B384 Q35159629-826B3EF9-34E3-4DA5-A3D0-C8B0A97D56C9 Q35190872-8CE3B436-4097-4AC7-935A-643FA2A49AF7 Q35365324-DAF6D8CA-FB0E-40F4-AEEB-87411467B0EE Q35546429-63E5E440-63E0-43BA-93A0-FCF46DCF8ECA Q35553464-0C78583F-0566-479C-90B2-4B0C5E4E33A7 Q35555217-AA226C2A-6B17-42B6-80B8-4A69844365B4 Q35555441-DF7E1072-49E8-4512-B752-4608367B3D25 Q35630047-A5EF1460-DA8D-4AFE-BD9E-010E4DA5566C Q35637808-CC83F52F-F0C0-4E53-8403-BF54A88A3DDA Q35775635-130CF7D9-79D0-425F-B53E-76D42D5B433E Q35814091-859E23B8-60E5-4A79-9ACF-11446836499E Q35834289-BE795BE2-AC01-40F4-97DC-C3223EE5B0C5 Q35911142-A6C505F6-0F29-4263-99BA-2240650BFD67 Q35953321-AAA54897-F346-4545-A7FC-B53B022D9D3E Q35967186-1BE1F48D-F249-4A6B-A8D5-939E497A4AD5 Q36048817-6255EC13-CC71-4359-A979-556ECBBE1AC8 Q36142613-F42311D6-BD82-434F-826F-C4AC91E31C34 Q36166363-42F6C7D1-00E1-4897-9701-65E902E80C58 Q36169364-7726592B-BC24-47E9-A832-44C787D95C6C

P2860

Molecular action of methotrexate in inflammatory diseases

http://www.wikidata.org/entity/Q24534771

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Molecular action of methotrexate in inflammatory diseases

@ast

Molecular action of methotrexate in inflammatory diseases

@en

Molecular action of methotrexate in inflammatory diseases

@en-gb

Molecular action of methotrexate in inflammatory diseases

@nl

type

label

Molecular action of methotrexate in inflammatory diseases

@ast

Molecular action of methotrexate in inflammatory diseases

@en

Molecular action of methotrexate in inflammatory diseases

@en-gb

Molecular action of methotrexate in inflammatory diseases

@nl

prefLabel

Molecular action of methotrexate in inflammatory diseases

@ast

Molecular action of methotrexate in inflammatory diseases

@en

Molecular action of methotrexate in inflammatory diseases

@en-gb

Molecular action of methotrexate in inflammatory diseases

@nl

P1433

Q24534771-68CE6DA1-F6D7-4A81-80F2-A1A7C97325B1

Q24534771-C461FADA-8263-48F6-AB89-08E698279F6A

P1476

Q24534771-334B498F-6455-4CEA-A616-45710533872C

P2093

Q24534771-81BB3EB5-E477-47CD-9617-82CD88BDD5C1

Q24534771-A52E0E7F-2873-4935-A958-807717A9A794

P2860

Q24534771-013F15BF-BEEB-4890-A784-CA504C8DA3A7

Q24534771-0190654C-AA9E-4A6B-BF89-80C10E53BDC5

Q24534771-082E6ED0-52DD-42CD-B18D-A5C8F5EA1944

Q24534771-176A662B-4B67-4F38-8936-3B9B7975B564

Q24534771-1AA1302B-1A85-4595-BC70-BA96FC3E5319

Q24534771-1DA61473-0802-4EF2-8D24-6A4E20EFA9BE

Q24534771-217E35F9-A2BC-4142-81D6-0D352884F5B8

Q24534771-238F3694-8EA6-4552-9699-1DCA2190D147

Q24534771-2468BE71-EF5B-4D8D-95B3-41B66FEA9ABB

Q24534771-2583F9F1-5407-42F3-A27F-EE7F3B9B6C3A

P2888

Q24534771-98F09B26-9BD5-4C1F-B658-08670E0AA154

P304

Q24534771-B9093EB4-D304-4569-B28A-6E4880FB8945

P31

Q24534771-400FC157-3DDA-4A89-A9A3-273E2F5CA7A3

Q24534771-E222C90E-6B59-4F35-A3A3-B17C6F671F96

P3181

Q24534771-DB2AB128-2B8B-48FA-BDED-809A20B481AE

P356

Q24534771-75E7EDEE-2F06-4791-AE17-8DC3E7290329

P407

Q24534771-70BAEA62-7C12-425F-A57E-DBF9B084195E

P433

Q24534771-94EC128E-625D-411E-85DC-5D6B648C6017

P478

Q24534771-D08E922F-DF21-4F8E-B065-EFFD2A149156

P577

Q24534771-93050ECC-CBD3-4B0B-B811-EF372147A319

P5875

Q24534771-31AFCEB5-D14D-45E2-863F-28FB43624758

P6179

Q24534771-66415A94-1044-4EC0-91F0-12F7871F9589

P698

Q24534771-3BD7FE4B-BE2C-447A-B08F-AFFF853A11CF

P921

Q24534771-A491386E-7451-4A14-A291-4A1420885574

Q24534771-A9F67576-7943-4010-BF2F-B79EC3A48748

Q24534771-CBCA56D4-50C0-42C3-BB94-9D8E9BFCD97C

P932

Q24534771-5B168301-6F1D-4C5F-BBAF-FE78EEA4CA32

P3181

P356

P1433

Arthritis Research and Therapy

Arthritis Research

P1476

Molecular action of methotrexate in inflammatory diseases

@en

P2093

Bruce N Cronstein

http://www.w3.org/2001/XMLSchema#string

Edwin S L Chan

http://www.w3.org/2001/XMLSchema#string

P2860

Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function

Anti-cytokine therapy in chronic destructive arthritis

Macrophages in rheumatoid arthritis

Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation

Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists.

Protein tyrosine phosphatase-dependent proteolysis of focal adhesion complexes in endothelial cell apoptosis.

Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis.

Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.

Methotrexate for rheumatoid arthritis.

The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

P2888

P304

266-273

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3726324

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/AR419

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11270990

http://www.w3.org/2001/XMLSchema#string

P6179

1012915794

http://www.w3.org/2001/XMLSchema#string

P698

12106498

http://www.w3.org/2001/XMLSchema#string

P921

rheumatoid arthritis

heterocyclic compound

P932

128935

http://www.w3.org/2001/XMLSchema#string